Consensus Cybin Inc.

Equities

Market Closed - Nyse Other stock markets 16:00:00 2024-05-06 EDT			5-day change	1st Jan Change
0.368 ^USD	+5.14%		+5.14%	-10.24%

04-17	Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	MT
04-16	Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	MT

7608513.5pic4VRFP2Eufv_k3E66E0xx53gd9R_oE12FsLrkpq4.ocvVzD4IbxNGO5GgmSj4TCUBpQwqtGqmTCzHyPuQ6dmN896AYhB3AndIxw~81aef586b8cf374f0101f4d4d7d52651

HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating	11-17	MT
Oppenheimer Adjusts Cybin Price Target to $4 From $4.50, Maintains Outperform Rating	23-08-15	MT
Canaccord Genuity Adjusts Price Target on Cybin to $5 From $6, Maintains Buy Rating	23-08-11	MT
Stifel Nicolaus Adjusts Cybin's Price Target to $1.13 From $1.10, Maintains Speculative Buy Rating	23-07-03	MT
Canaccord Genuity Trims Price Target on Cybin to $6 From $7, Maintains Buy Rating	23-07-03	MT
EF Hutton Initiates Cybin at Buy With $3 Price Target	22-12-16	MT
Stifel Nicolaus Adjusts Cybin Price Target to CA$3 From CA$8.25, Maintains Speculative Buy Rating	22-08-24	MT
Stifel Nicolaus Adjusts Cybin PT to CA$8.25 From CA$10, Maintains Speculative Buy Rating	21-11-23	MT
HC Wainwright Adjusts Cybin's Price Target to $10 From $8, Reiterates Buy Rating	21-11-22	MT
CYBIN : Oppenheimer Initiates Coverage on Cybin With Outperform Rating, $7 Price Target	21-10-05	MT
CYBIN : Canaccord Genuity Adjusts Cybin's Price Target to $7 From $6, Reiterates Buy Rating	21-08-27	MT
CYBIN : Cantor Fitzgerald Starts Cybin at Overweight with $9 Price Target	21-08-26	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.5027 CAD

Average target price

6.075 CAD

Spread / Average Target

+1,108.55%

High Price Target

8.083 CAD

Spread / Highest target

+1,508.01%

Low Price Target

4.105 CAD

Spread / Lowest Target

+716.64%